References

References cited in this web site


Barlogie, B., Tricot, G.J., van Rhee, F., Angtuaco, E., Walker, R., Epstein, J., Shaughnessy, J.D., Jagannath, S., Bolejack, V., Gurley, J., Hoering, A., Vesole, D., Desikan, R., Siegel, D., Mehta, J., Singhal, S., Munshi, N.C., Dhodapkar, M., Jenkins, B., Attal, M., Harousseau, J.L., and Crowley, J. 2006. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 135(2): 158-164.


Barlogie, B., Attal, M., Crowley, J., van Rhee, F., Szymonifka, J., Moreau, P., Durie, B.G., and Harousseau, J.L. 2010. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol 28(7): 1209-1214.


Berenson, J.R., Hillner, B.E., Kyle, R.A., Anderson, K., Lipton, A., Yee, G.C., and Biermann, J.S. 2002. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin.Oncol. 20(17): 3719-3736.


Brunelle, J.K., Ryan, J., Yecies, D., Opferman, J.T., and Letai, A. 2009. MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts. J Cell Biol 187(3): 429-442.


Blanpain, C., Mohrin, M., Sotiropoulou, P.A., and Passegue, E. 2011. DNA-damage response in tissue-specific and cancer stem cells. Cell Stem Cell 8(1): 16-29.


Cavo, M., Tacchetti, P., Patriarca, F., Petrucci, M.T., Pantani, L., Galli, M., Di Raimondo, F., Crippa, C., Zamagni, E., Palumbo, A., Offidani, M., Corradini, P., Narni, F., Spadano, A., Pescosta, N., Deliliers, G.L., Ledda, A., Cellini, C., Caravita, T., Tosi, P., and Baccarani, M. 2010. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. The Lancet 376(9758): 2075-2085.


Dalby, K.N., Tekedereli, I., Lopez-Berestein, G., and Ozpolat, B. 2010. Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy 6(3): 322- 329.


Damiano, J.S., Cress, A.E., Hazlehurst, L.A., Shtil, A.A., and Dalton, W.S. 1999. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93(5): 1658-1667.


Davies, F.E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.T., Lin, B., Podar, K., Gupta, D., Chauhan, D., Treon, S.P., Richardson, P.G., Schlossman, R.L., Morgan, G.J., Muller, G.W., Stirling, D.I., and Anderson, K.C. 2001. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98(1): 210-216.


Dick, J.E. 2008. Stem cell concepts renew cancer research. Blood 112(13): 4793-4807.


Durie, B.G., Harousseau, J.L., Miguel, J.S., Blade, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G., and Rajkumar, S.V. 2006. International uniform response criteria for multiple myeloma. Leukemia 20(9): 1467-1473.


Engelhardt, M., Kleber, M., Udi, J., Wasch, R., Spencer, A., Patriarca, F., Knop, S., Bruno, B., Gramatzki, M., Morabito, F., Kropff, M., Neri, A., Sezer, O., Hajek, R., Bunjes, D., Boccadoro, M., Straka, C., Cavo, M., Polliack, A., Einsele, H., and Palumbo, A. 2010. Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma 51(8): 1424-1443.


Erez, N., Truitt, M., Olson, P., Arron, S.T., and Hanahan, D. 2010. Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NFkappaB- Dependent Manner. Cancer Cell 17(2): 135-147.


Escoubet-Lozach, L., Lin, I.L., Jensen-Pergakes, K., Brady, H.A., Gandhi, A.K., Schafer, P.H., Muller, G.W., Worland, P.J., Chan, K.W., and Verhelle, D. 2009. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer research 69(18): 7347-7356


Facon, T., Mary, J.Y., Hulin, C., Benboubker, L., Attal, M., Pegourie, B., Renaud, M., Harousseau, J.L., Guillerm, G., Chaleteix, C., Dib, M., Voillat, L., Maisonneuve, H., Troncy, J., Dorvaux, V., Monconduit, M., Martin, C., Casassus, P., Jaubert, J., Jardel, H., Doyen, C., Kolb, B., Anglaret, B., Grosbois, B., Yakoub-Agha, I., Mathiot, C., and Avet-Loiseau, H. 2007. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. The Lancet 370(9594): 1209-1218.


Fonseca, R., Barlogie, B., Bataille, R., Bastard, C., Bergsagel, P.L., Chesi, M., Davies, F.E., Drach, J., Greipp, P.R., Kirsch, I.R., Kuehl, W.M., Hernandez, J.M., Minvielle, S., Pilarski, L.M., Shaughnessy, J.D., Jr., Stewart, A.K., and Avet-Loiseau, H. 2004. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer research 64(4): 1546-1558.


Goldschmidt, H., Sonneveld, P., Cremer, F.W., van der Holt, B., Westveer, P., Breitkreutz, I., Benner, A., Glasmacher, A., Schmidt-Wolf, I.G., Martin, H., Hoelzer, D., Ho, A.D., and Lokhorst, H.M. 2003. Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. Ann. Hematol. 82(10): 654-659.


Gorgun, G., Calabrese, E., Soydan, E., Hideshima, T., Perrone, G., Bandi, M., Cirstea, D., Santo, L., Hu, Y., Tai, Y.T., Nahar, S., Mimura, N., Fabre, C., Raje, N., Munshi, N., Richardson, P., and Anderson, K.C. 2010. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 116(17): 3227-3237.


Greipp, P.R., San Miguel, J., Durie, B.G., Crowley, J.J., Barlogie, B., Blade, J., Boccadoro, M., Child, J.A., Avet-Loiseau, H., Kyle, R.A., Lahuerta, J.J., Ludwig, H., Morgan, G., Powles, R., Shimizu, K., Shustik, C., Sonneveld, P., Tosi, P., Turesson, I., and Westin, J. 2005. International staging system for multiple myeloma. J Clin Oncol 23(15): 3412-3420.


Harousseau, J.L., Attal, M., Avet-Loiseau, H., Marit, G., Caillot, D., Mohty, M., Lenain, P., Hulin, C., Facon, T., Casassus, P., Michallet, M., Maisonneuve, H., Benboubker, L., Maloisel, F., Petillon, M.O., Webb, I., Mathiot, C., and Moreau, P. 2010. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 28(30): 4621-4629.


Harousseau, J.L., and Moreau, P. 2009. Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 360(25): 2645-2654.


Hose, D., Moreaux, J., Meissner, T., Seckinger, A., Goldschmidt, H., Benner, A., Mahtouk, K., Hillengass, J., Reme, T., De, V.J., Hundemer, M., Condomines, M., Bertsch, U., Rossi, J.F., Jauch, A., Klein, B., and Mohler, T. 2009a. Induction of angiogenesis by normal and malignant plasma cells. Blood 114(1): 128-143.


Hose, D., Reme, T., Meissner, T., Moreaux, J., Seckinger, A., Lewis, J., Benes, V., Benner, A., Hundemer, M., Hielscher, T., Shaughnessy, J.D., Jr., Barlogie, B., Neben, K., Kramer, A., Hillengass, J., Bertsch, U., Jauch, A., De, V.J., Rossi, J.F., Mohler, T., Blake, J., Zimmermann, J., Klein, B., and Goldschmidt, H. 2009b. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood 113(18): 4331-4340.


Huang, X., Liberto, M.D., Jayabalan, D., Hussein, M., Randolph, S., Niesvizky, R., and Chen-Kiang, S. 2010. Lenalidomide Targets Myeloma Cells Preferentially During Prolonged Early G1 Arrest but Not Synchronization Into S Phase by Selective and Reversible Inhibition of CDK4/CDK6 through Loss of IRF-4. ASH Annual Meeting Abstracts 116(21): 449-.


Li, S., Gill, N., and Lentzsch, S. 2010a. Recent advances of IMiDs in cancer therapy. Current opinion in oncology 22(6): 579-585.


Li, S., Pal, R., Monaghan, S., Schafer, P., Ouyang, H., Mapara, M.Y., and Lentzsch, S. 2010b. C/EBPb Is a Critical Mediator of Resistance to IMiD(R) Immunomodulatory Compounds and Affected by IMiD Compounds Via Control of Protein Translation. ASH Annual Meeting Abstracts 116(21): 135-.


Markovina, S., Callander, N.S., O'Connor, S.L., Xu, G., Shi, Y., Leith, C.P., Kim, K., Trivedi, P., Kim, J., Hematti, P., and Miyamoto, S. 2010. Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. Mol Cancer 9: 176.


McDermott, U., Downing, J.R., and Stratton, M.R. 2011. Genomics and the continuum of cancer care. The New England journal of medicine 364(4): 340-350.


Michael, M., Bruns, I., Bolke, E., Zohren, F., Czibere, A., Safaian, N.N., Neumann, F., Haas, R., Kobbe, G., and Fenk, R. 2010. Bendamustine in patients with relapsed or refractory multiple myeloma. Eur J Med Res 15(1): 13-19.


Palumbo, A., Delforge, M., Catalano, J., Hajek, R., Kropff, M., Petrucci, M.T., Yu, Z., Herbein, L., Mei, J.M., Jacques, C.J., and Dimopoulos, M.A. 2010a. A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone In Patients >= 65 Years with Newly Diagnosed Multiple Myeloma (NDMM): Continuous Use of Lenalidomide Vs Fixed-Duration Regimens. ASH Annual Meeting Abstracts 116(21): 622.


Palumbo, A., Gay, F., Falco, P., Crippa, C., Montefusco, V., Patriarca, F., Rossini, F., Caltagirone, S., Benevolo, G., Pescosta, N., Guglielmelli, T., Bringhen, S., Offidani, M., Giuliani, N., Petrucci, M.T., Musto, P., Liberati, A.M., Rossi, G., Corradini, P., and Boccadoro, M. 2010b. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 28(5): 800-807.


Perez, L.E., Parquet, N., Meads, M., Anasetti, C., and Dalton, W. 2010. Bortezomib restores stromamediated APO2L/TRAIL apoptosis resistance in multiple myeloma. European journal of haematology 84(3): 212-222.


Perez-Andres, M., Paiva, B., Nieto, W.G., Caraux, A., Schmitz, A., Almeida, J., Vogt, R.F., Jr., Marti, G.E., Rawstron, A.C., Van Zelm, M.C., Van Dongen, J.J., Johnsen, H.E., Klein, B., and Orfao, A. 2010. Human peripheral blood B-cell compartments: a crossroad in B-cell traffic. Cytometry B Clin Cytom 78 Suppl 1: S47-60.


Pfeifer, S., Perez-Andres, M., Ludwig, H., Sahota, S.S. and Zojer, N. 2011. Evaluating the clonal hierarchy in light-chain multiple myeloma: implications against the myeloma stem cell hypothesis. Leukemia 25(7):1213-1216.


Quinn, J., Glassford, J., Percy, L., Munson, P., Marafioti, T., Rodriguez-Justo, M., and Yong, K. 2011. APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status. Blood 117(3): 890-901


Quintas-Cardama, A., Kantarjian, H.M., and Cortes, J.E. 2009. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 16(2): 122-131.


Raab, M.S., Podar, K., Breitkreutz, I., Richardson, P.G., and Anderson, K.C. 2009. Multiple myeloma. Lancet 374(9686): 324-339.


Rohwer, N., Dame, C., Haugstetter, A., Wiedenmann, B., Detjen, K., Schmitt, C.A., and Cramer, T. 2010. Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB. PLoS One 5(8): e12038.


San Miguel, J.F., Schlag, R., Khuageva, N.K., Dimopoulos, M.A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M.T., Palumbo, A., Samoilova, O.S., Dmoszynska, A., Abdulkadyrov, K.M., Schots, R., Jiang, B., Mateos, M.V., Anderson, K.C., Esseltine, D.L., Liu, K., Cakana, A., van de Velde, H., and Richardson, P.G. 2008. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N.Engl.J.Med. 359(9): 906-917.


Sarkadi, B., Homolya, L., Szakacs, G., and Varadi, A. 2006. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 86(4): 1179- 1236.


Seckinger, A., Meissner, T., Moreaux, J., Goldschmidt, H., Fuhler, G.M., Benner, A., Hundemer, M., Reme, T., Shaughnessy, J.D., Jr., Barlogie, B., Bertsch, U., Hillengass, J., Ho, A.D., Pantesco, V., Jauch, A., De Vos, J., Rossi, J.F., Mohler, T., Klein, B., and Hose, D. 2009. Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene 28(44): 3866-3879.


Sonneveld, P., Schmidt-Wolf, I., van der Holt, B., Jarari, L.e., Bertsch, U., Salwender, H., Zweegman, S., Vellenga, E., Schubert, J., Blau, I.W., Jie, A., Beverloo, B., Hose, D., Jauch, A., van de Velde, H., Schaafsma, M., Lindemann, W., Kersten, M.J., Duehrsen, U., Delforge, M., Weisel, K., Croockewit, S., Martin, H., Wittebol, S., Scheid, C., Bos, G., van Marwijk-Kooy, M., Wijermans, P., Lokhorst, H., and Goldschmidt, H. 2010. HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM). Blood (ASH Annual Meeting Abstracts) 116(21): 40.


Stratton, M.R., Campbell, P.J., and Futreal, P.A. 2009. The cancer genome. Nature 458(7239): 719- 724.


Stephens, P.J., Greenman, C.D., Fu, B., Yang, F., Bignell, G.R., Mudie, L.J., Pleasance, E.D., Lau, K.W., Beare, D., Stebbings, L.A., McLaren, S., Lin, M.L., McBride, D.J., Varela, I., Nik-Zainal, S., Leroy, C., Jia, M., Menzies, A., Butler, A.P., Teague, J.W., Quail, M.A., Burton, J., Swerdlow, H., Carter, N.P., Morsberger, L.A., Iacobuzio-Donahue, C., Follows, G.A., Green, A.R., Flanagan, A.M., Stratton, M.R., Futreal, P.A., and Campbell, P.J. 2011. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144(1): 27-40.


Verhelle, D., Corral, L.G., Wong, K., Mueller, J.H., Moutouh-de Parseval, L., Jensen-Pergakes, K., Schafer, P.H., Chen, R., Glezer, E., Ferguson, G.D., Lopez-Girona, A., Muller, G.W., Brady, H.A., and Chan, K.W. 2007. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer research 67(2): 746-755.


Weinstein, R.S., Chen, J.R., Powers, C.C., Stewart, S.A., Landes, R.D., Bellido, T., Jilka, R.L., Parfitt, A.M., and Manolagas, S.C. 2002. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J.Clin.Invest 109(8): 1041-1048.


Zhan, F., Hardin, J., Kordsmeier, B., Bumm, K., Zheng, M., Tian, E., Sanderson, R., Yang, Y., Wilson, C., Zangari, M., Anaissie, E., Morris, C., Muwalla, F., van Rhee, F., Fassas, A., Crowley, J., Tricot, G., Barlogie, B., and Shaughnessy Jr, J. 2002. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99: 1745-1757.


Zhan, F., Huang, Y., Colla, S., Stewart, J.P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., Anaissie, E., Hollmig, K., Pineda-Roman, M., Tricot, G., van Rhee, F., Walker, R., Zangari, M., Crowley, J., Barlogie, B., and Shaughnessy, J.D., Jr. 2006. The molecular classification of multiple myeloma. Blood 108(6): 2020-2028.


Zheng, Y., Cai, Z., Wang, S., Zhang, X., Qian, J., Hong, S., Li, H., Wang, M., Yang, J., and Yi, Q. 2009. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 114(17): 3625-3628.


Zheng, T., Wang, J., Chen, X., and Liu, L. 2010. Role of microRNA in anticancer drug resistance. Int J Cancer 126(1): 2-10.


Zhou, Y., Chen, L., Barlogie, B., Stephens, O., Wu, X., Williams, D.R., Cartron, M.A., van Rhee, F., Nair, B., Waheed, S., Pineda-Roman, M., Alsayed, Y., Anaissie, E., and Shaughnessy, J.D., Jr. 2010. High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci U S A 107(17): 7904-7909.



Overmyr © 2012